Please substitute the following paragraph on page 22, beginning at line 1:

Oldham, R.K. (1985) "Biologicals for cancer treatment: interferons" *Hospital Practice* 20(12):71-91.

Please substitute the following paragraph on page 22, beginning at line 10:

Quesada, J.R., J. Reuben, J.T. Manning, E.M. Hersh, J.U. Gutterman (1984) "Alpha Interferon for Induction of Remission in Hairy-Cell Leukemia" *New England Journal of Medicine* 310:15-18.

In the Claims

Please cancel claims 1-24, without prejudice.

Please add the following new claims 25-39:

25. A method for suppressing or inhibiting IgE production, said method comprising administering an effective amount of a type I interferon, or a biologically active fragment thereof.

26. The method according to claim 25, wherein said type I interferon is selected from the group consisting of interferon alpha, interferon beta, interferon tau, and interferon gamma.

27. The method according to claim 26, wherein said type I interferon is interferon tau.

28. The method according to claim 25, wherein said type I interferon is a chimeric interferon comprising part of at least two interferons selected from the group consisting of interferon alpha, interferon beta, interferon tau, and interferon gamma.

29. The method according to claim 28, wherein said chimeric interferon comprises a mammalian interferon tau amino terminus and a human type I interferon carboxy terminus other than interferon tau.

30. The method according to claim 29, wherein said mammalian interferon tau amino terminus is from a mammal selected from the group consisting of primate, ovine, and bovine.

31. The method according to claim 29, wherein said chimeric interferon comprises amino acid residues from about 1 to about 27 of ovine interferon tau and amino acid residues from about 28 to about 166 of human interferon alpha.

32. The method according to claim 31, wherein said interferon alpha is interferon alpha D.

33. The method according to claim 25, wherein said type I interferon is administered to a person or animal in need of suppression or inhibition of IgE production.

34. The method according to claim 25, wherein said suppression or inhibition of IgE production occurs through inhibition of B-cell IgE secretion or inhibition of B-cell proliferation.

35. The method according to claim 33, wherein said type I interferon is administered by routes selected from the group consisting of oral administration, parenteral administration, subcutaneous administration and intravenous administration.

36. The method according to claim 35, wherein said person or animal is afflicted with, or predisposed to, an IgE-related condition.

37. The method according to claim 36, wherein said IgE-related condition is an allergic condition selected from the group consisting of allergic rhinitis, atopic dermatitis, bronchial asthma and food allergy.

38. The method according to claim 25, wherein said type I interferon is administered *in vitro*.

39. The method according to claim 25, wherein said type I interferon is formulated in a pharmaceutically acceptable carrier or diluent.